In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway […]readmore
Tags : TCR T-Cell Therapy